Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC1419 | PF-4708671 | p70S6K | PI3K/mTOR | 5.2795 | 0.3488 | 0.1117 | -0.0019 | 1.0898 | 4.6502 | 0.97858 |
| SUM159PT | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.6876 | 0.3173 | -0.0017 | 0.0000 | Inf | 0.45421 |
| HCC1937 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0406 | -0.0017 | 0.0000 | Inf | -4.6521 |
| CAMA-1 | Palbociclib | CDK4/6 | Cell cycle | 0.074216 | 0.2816 | 0.3530 | -0.0016 | 1.1861 | 0.038743 | 0.99185 |
| HCC1419 | Cabozantinib | VEGFR2/MET | RTK | 10.7779 | 0.6224 | -0.0111 | -0.0016 | 5.0000 | 12.9768 | 0.90031 |
| MCF 10A | Trametinib | MEK | MAPK/nRTK | 0.0033619 | 0.2252 | 0.5266 | -0.0015 | 1.2096 | 0.0021432 | 0.99763 |
| CAL-120 | Alpelisib | PI3Ka | PI3K/mTOR | 21.5328 | 0.6075 | 0.0922 | -0.0015 | 0.5034 | 190.956 | 0.93579 |
| MDA-MB-453 | Cisplatin | Chemo | Chemotherapy | 3.4106 | 0.1328 | 0.0938 | -0.0013 | 3.0256 | 3.151 | 0.9887 |
| HCC70 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.9361 | -0.0281 | -0.0013 | 0.0000 | Inf | -0.054738 |
| MCF 10A | Abemaciclib | CDK4/6 | Cell cycle | 0.34027 | 0.1513 | 0.3811 | -0.0012 | 0.5714 | 0.28176 | 0.99756 |
| HCC1419 | Olaparib | PARP | Misc | Inf | 0.6322 | 0.0273 | -0.0012 | 2.1535 | 5.2752 | 0.95353 |
| PDXHCI002 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8732 | -0.0268 | -0.0011 | 0.0000 | Inf | 0.45924 |
| BT-549 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0401 | -0.0011 | 0.0000 | Inf | -9.2879 |
| SUM159PT | Saracatinib | SRC | MAPK/nRTK | 13.9057 | 0.5624 | 0.0724 | -0.0011 | 0.9804 | 8.3037 | 0.99931 |
| CAL-85-1 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0418 | -0.0009 | 0.0000 | Inf | -4.681 |
| SUM1315MO2 | A-1210477 | Mcl-1 | Misc | Inf | 0.7399 | -0.0234 | -0.0009 | 3.9393 | 9.1387 | 0.79269 |
| HME1 | Olaparib | PARP | Misc | 25.4252 | 0.5911 | 0.0258 | -0.0009 | 1.9303 | 5.1651 | 0.96396 |
| MDA-MB-231 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9254 | 0.0073 | -0.0008 | 0.0000 | Inf | 0.28623 |
| HCC1428 | Cabozantinib | VEGFR2/MET | RTK | Inf | 0.6310 | 0.0204 | -0.0008 | 2.9241 | 4.2982 | 0.94377 |
| CAMA-1 | Olaparib | PARP | Misc | 14.8517 | 0.6788 | 0.0527 | -0.0008 | 1.4312 | 31.9803 | 0.84248 |
| MCF 10A | Olaparib | PARP | Misc | 59.3998 | 0.7945 | 0.0408 | -0.0007 | 0.6167 | 350.419 | 0.98306 |
| HCC38 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9760 | -0.0258 | -0.0006 | 0.0000 | Inf | -0.90907 |
| MDA-MB-134-VI | Olaparib | PARP | Misc | Inf | 0.5510 | 0.0145 | -0.0006 | 4.9904 | 4.9955 | 0.86393 |
| MDA-MB-231 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.7110 | 0.2246 | -0.0006 | 0.0000 | Inf | 0.54965 |
| SUM159PT | Palbociclib | CDK4/6 | Cell cycle | 1.1058 | 0.3876 | 0.1990 | -0.0006 | 0.6326 | 0.40763 | 0.99661 |